Selected stock price target news of the day - January 10th, 2025

By: Matthew Otto

Catalyst Pharmaceuticals Settles Patent Litigation Over FIRDAPSE®

Catalyst Pharmaceuticals announced a settlement agreement with SERB S.A. and Teva Pharmaceuticals USA, resolving patent litigation over FIRDAPSE® (amifampridine) 10 mg tablets. The dispute stemmed from Teva’s Abbreviated New Drug Application (ANDA), which sought FDA approval to market a generic version of FIRDAPSE before patent expiration.

Under the agreement, Teva is restricted from marketing its generic version in the U.S. until February 25, 2035, pending FDA approval, barring certain customary exceptions. The settlement concludes all ongoing patent litigation between Catalyst, SERB, and Teva in the U.S. District Court for the District of New Jersey. However, related lawsuits against Hetero (concerning all Orange Book-listed patents) and Lupin (targeting Catalyst’s patent expiring in 2037) remain active.

This agreement will be submitted for review to the U.S. Federal Trade Commission and the Department of Justice, as required by law. FIRDAPSE®, a leading treatment for Lambert-Eaton myasthenic syndrome (LEMS), generated approximately $245 million in revenue for Catalyst in 2023.

FIRDAPSE is a crucial therapy for patients with Lambert-Eaton myasthenic syndrome (LEMS), a rare neuromuscular disorder affecting approximately 3,000 individuals in the United States and an estimated 15,000 worldwide. With Catalyst reporting $245 million in FIRDAPSE revenues in 2023.

Analyst Ratings Reflect Optimism Following Patent Settlement

HC Wainwright & Co. analyst Andrew Fein maintained a Buy rating while raising the price target from $30 to $35.
BofA Securities analyst Jason Gerberry yesterday reiterated a Buy rating and the price target at $30

Which Analyst has the best track record to show on CPRX?

Analyst Andrew Fein (HC WAINWRIGHT) currently has the highest performing score on CPRX with 3/13 (23.08%) price target fulfillment ratio. His price targets carry an average of $6.14 (25.73%) potential upside. Catalyst Pharmaceuticals stock price reaches these price targets on average within 215 days.

Intuit Launches Innovative Tax Refund Solutions for 2024 Season

Intuit has introduced a suite of solutions designed to expedite tax refunds for the 2024 tax season. Among the highlights is TurboTax’s first-of-its-kind “5 Days Early Refund Offering,” which guarantees federal refunds five days ahead of the IRS settlement date for a $25 fee.

This service is available for refunds over $250 and is accessible regardless of the filer’s banking institution. Additionally, TurboTax continues its no-interest Refund Advance loan, offering up to $4,000 with approval in as little as 60 seconds after IRS acceptance.

A survey by Talker Research reveals the critical importance of faster refunds, especially for younger filers. For example, 93% of Gen Z respondents expect a refund this year, with 35% prioritizing rent payments and another 35% using it to pay off debt. Across generations, most plan to use refunds, averaging over $3,000, to cover necessities like food and housing, with 43% intending to bolster savings.

Analyst Reaffirms Rating and Target Amid Innovations

Piper Sandler analyst Arvind Ramnani reiterated an Overweight rating and a $765 price target.

Which Analyst has the best track record to show on INTU?

Analyst Keith Weiss (MORGAN STANLEY) currently has the highest performing score on INTU with 22/27 (81.48%) price target fulfillment ratio. His price targets carry an average of $82.18 (12.69%) potential upside. Intuit stock price reaches these price targets on average within 101 days.

Halozyme Provides Preliminary 2024 Results and Increases 2025 Financial Guidance

Halozyme Therapeutics has announced preliminary unaudited financial results for 2024 and updated guidance for 2025. 2024 total revenue is anticipated to range between $970 million and $1,020 million, with royalty revenue estimated at $550 million to $565 million. Net income is expected to be between $419 million and $443 million, while adjusted EBITDA is projected at $595 million to $625 million. Non-GAAP diluted EPS for 2024 is estimated at $4.00 to $4.20, reflecting the company’s stable performance. These preliminary figures remain subject to finalization.

For 2025, Halozyme has raised its financial outlook, now projecting total revenue between $1,150 million and $1,225 million, a year-over-year increase of 16% to 23%. Adjusted EBITDA is expected to grow by 24% to 32%, ranging from $755 million to $805 million. Non-GAAP diluted EPS is forecasted at $4.95 to $5.35, representing growth of 21% to 30%.

Analyst Maintains Rating and Raises Price Target Following 2025 Guidance

HC Wainwright & Co. analyst Mitchell Kapoor kept a Buy rating and raised the price target from $68 to $70.

Which Analyst has the best track record to show on HALO?

Analyst Joseph Catanzaro (PIPER SANDLER) currently has the highest performing score on HALO with 14/14 (100%) price target fulfillment ratio. His price targets carry an average of $-6.47 (-11.07%) potential downside. Halozyme Therapeutics stock price reaches these price targets on average within 140 days.